2024-01-24
„AiCuris and the German Center for Infection Research (DZIF) sign Collaboration and License Option Agreement“
The cooperation provides us with the opportunity to combine exceptional German antiviral research with our development capabilities and clinical expertise to develop novel therapies for immunocompromised patients.
2024-01-09
AiCuris Received 15 Million Euros Milestone Payment from Licensing Partner MSD Following EMA Approval of PREVYMIS®
PREVYMIS® received european approval for prophylaxis of Cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk.
2024-01-04
AiCuris Senior Management heading to San Francisco for the J.P. Morgan Annual Healthcare Conference from January 8th–11th
Meet with our CEO Larry Edwards and CFO Sabrina Kuttruff-Coqui at the J.P. Morgan Annual Healthcare Conference.
